SIGN UP TO VIEW THE FULL ARTICLE

Receive a 90-day free trial of Celltelligence and get instant access to our full offering.


EMAIL BLASTS

Curated cell therapy industry news in your inbox multiple times each week

SEARCHABLE LIBRARY

A full archive of cell therapy news, insights, and context

THE MAP

A 24/7 information center that lets you make unique connections

The price for access is $0.00.

Do you have a discount code? Click here to enter your discount code.

Account Information

LEAVE THIS BLANK

By selecting this, I agree to receive emails from celltelligence.com.

Already have an account? Log in here
RETURN TO HOME
$0
Autologous, TCR

TCR2 on Track to Identify Gavo-cel’s (Mesothelin TRuC-T) RP2D by YE 2021; Will Checkpoint Inhibitors Improve Gavo-cel’s Efficacy? ESMO 2021 Day 2

Here is a brief preview of this blast: On Friday, September 17, TCR2 Tx held an investor call (press release / presentation) highlighting updated clinical data presented at ESMO from gavo-cel's (TC-210; autologous mesothelin TRuC-T) Ph1/2 trial in advanced mesothelin-expressing cancers. Below, Celltelligence provides insights on TCR2’s approach to find gavo-cel’s RP2D, and how combining a PD1 inhibitor with gavo-cel could improve the TRuC-T’s efficacy profile, while discussing gavo-cel’s potential expansion into other indications.

About The Author

The Celltelligence Team

|
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.